TAIGEN BIOTECHNOLOGY CO., LTD.
🇹🇼Taiwan
- Country
- 🇹🇼Taiwan
- Ownership
- Public, Subsidiary
- Established
- 2001-05-01
- Employees
- 101
- Market Cap
- -
Clinical Trials
15
Active:0
Completed:15
Trial Phases
4 Phases
Phase 1:6
Phase 2:6
Phase 3:2
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (15 trials with phase data)• Click on a phase to view related trials
Phase 1
6 (40.0%)Phase 2
6 (40.0%)Phase 3
2 (13.3%)Phase 4
1 (6.7%)Oral Nemonoxacin in Treating Elderly Patients With CAP
- First Posted Date
- 2021-11-24
- Last Posted Date
- 2021-11-24
- Lead Sponsor
- TaiGen Biotechnology Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT05133752
- Locations
- 🇨🇳
Tri-Service General Hospital, Taipei, Taiwan
To Evaluate the Efficacy and Safety of TG-1000 Compared With Placebo in Adult Patients With Acute Uncomplicated Influenza Virus Infection
- First Posted Date
- 2021-01-12
- Last Posted Date
- 2022-03-09
- Lead Sponsor
- TaiGen Biotechnology Co., Ltd.
- Target Recruit Count
- 202
- Registration Number
- NCT04706468
- Locations
- 🇨🇳
Xiangya Hospital Central South University, Hunan, China
To Evaluate the Safety, Tolerability, and Pharmacokinetics Profiles of TG-1000 in Healthy Volunteers, and the Food Effect on Pharmacokinetics of Single Oral Dose of TG-1000 in Healthy Volunteers.
- First Posted Date
- 2020-07-31
- Last Posted Date
- 2021-01-07
- Lead Sponsor
- TaiGen Biotechnology Co., Ltd.
- Target Recruit Count
- 66
- Registration Number
- NCT04495322
- Locations
- 🇨🇳
Xiangya Hospital of Central South University, Changsha, Hunan, China
A Study Evaluating the Effect of a Single-dose Oral Administration of Nemonoxacin Capsule on QTc Intervals and Heart Rhythms of Healthy Subjects and the Influence of Food Intake on QTc Intervals and Pharmacokinetic Characteristics
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Placebo oral capsule
- First Posted Date
- 2017-12-05
- Last Posted Date
- 2017-12-06
- Lead Sponsor
- TaiGen Biotechnology Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT03362853
Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C Infection
Phase 2
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2015-01-19
- Last Posted Date
- 2023-07-14
- Lead Sponsor
- TaiGen Biotechnology Co., Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT02340962
- Locations
- 🇨🇳
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
- Prev
- 1
- 2
- 3
- Next
News
No news found